BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 12062387)

  • 1. Susceptibility of recent Canadian influenza A and B virus isolates to different neuraminidase inhibitors.
    Boivin G; Goyette N
    Antiviral Res; 2002 Jun; 54(3):143-7. PubMed ID: 12062387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants.
    Gubareva LV; Webster RG; Hayden FG
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3403-8. PubMed ID: 11709315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sensitivity of influenza viruses to zanamivir and oseltamivir: a study performed on viruses circulating in France prior to the introduction of neuraminidase inhibitors in clinical practice.
    Ferraris O; Kessler N; Lina B
    Antiviral Res; 2005 Oct; 68(1):43-8. PubMed ID: 16125799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of a human influenza type B strain with reduced sensitivity to neuraminidase inhibitor drugs.
    Hurt AC; McKimm-Breschkin JL; McDonald M; Barr IG; Komadina N; Hampson AW
    Virus Res; 2004 Jul; 103(1-2):205-11. PubMed ID: 15163511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Surveillance for neuraminidase inhibitor resistance in human influenza viruses from Australia.
    Hurt AC; Barr IG; Durrant CJ; Shaw RP; Sjogren HM; Hampson AW
    Commun Dis Intell Q Rep; 2003; 27(4):542-7. PubMed ID: 15508516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surveillance of influenza isolates for susceptibility to neuraminidase inhibitors during the 2000-2002 influenza seasons.
    Mungall BA; Xu X; Klimov A
    Virus Res; 2004 Jul; 103(1-2):195-7. PubMed ID: 15163509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phenotypic drug susceptibility assay for influenza virus neuraminidase inhibitors.
    McSharry JJ; McDonough AC; Olson BA; Drusano GL
    Clin Diagn Lab Immunol; 2004 Jan; 11(1):21-8. PubMed ID: 14715540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the anti-influenza virus activity of RWJ-270201 with those of oseltamivir and zanamivir.
    Bantia S; Parker CD; Ananth SL; Horn LL; Andries K; Chand P; Kotian PL; Dehghani A; El-Kattan Y; Lin T; Hutchison TL; Montgomery JA; Kellog DL; Babu YS
    Antimicrob Agents Chemother; 2001 Apr; 45(4):1162-7. PubMed ID: 11257030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Susceptibility of human influenza viruses from Australasia and South East Asia to the neuraminidase inhibitors zanamivir and oseltamivir.
    Hurt AC; Barr IG; Hartel G; Hampson AW
    Antiviral Res; 2004 Apr; 62(1):37-45. PubMed ID: 15026200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Zanamivir. A potent and selective inhibitor of influenza A and B viruses.
    Aoki FY; Hayden FG
    Clin Pharmacokinet; 1999; 36 Suppl 1():v-ix. PubMed ID: 10429834
    [No Abstract]   [Full Text] [Related]  

  • 11. Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir.
    McKimm-Breschkin J; Trivedi T; Hampson A; Hay A; Klimov A; Tashiro M; Hayden F; Zambon M
    Antimicrob Agents Chemother; 2003 Jul; 47(7):2264-72. PubMed ID: 12821478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses.
    Govorkova EA; Leneva IA; Goloubeva OG; Bush K; Webster RG
    Antimicrob Agents Chemother; 2001 Oct; 45(10):2723-32. PubMed ID: 11557461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro neuraminidase inhibitory activity of four neuraminidase inhibitors against clinical isolates of the influenza virus circulating in the Japanese 2013-2014 season.
    Ikematsu H; Kawai N; Iwaki N; Kashiwagi S
    J Infect Chemother; 2015 Sep; 21(9):634-8. PubMed ID: 26096495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro selection and characterization of influenza A (A/N9) virus variants resistant to a novel neuraminidase inhibitor, A-315675.
    Molla A; Kati W; Carrick R; Steffy K; Shi Y; Montgomery D; Gusick N; Stoll VS; Stewart KD; Ng TI; Maring C; Kempf DJ; Kohlbrenner W
    J Virol; 2002 Jun; 76(11):5380-6. PubMed ID: 11991966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A reverse genetics study of resistance to neuraminidase inhibitors in an influenza A/H1N1 virus.
    Abed Y; Goyette N; Boivin G
    Antivir Ther; 2004 Aug; 9(4):577-81. PubMed ID: 15456089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuraminidase inhibitor-resistant and -sensitive influenza B viruses isolated from an untreated human patient.
    Hurt AC; Iannello P; Jachno K; Komadina N; Hampson AW; Barr IG; McKimm-Breschkin JL
    Antimicrob Agents Chemother; 2006 May; 50(5):1872-4. PubMed ID: 16641465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuraminidase inhibitor susceptibility profile of pandemic and seasonal influenza viruses during the 2009-2010 and 2010-2011 influenza seasons in Japan.
    Dapat C; Kondo H; Dapat IC; Baranovich T; Suzuki Y; Shobugawa Y; Saito K; Saito R; Suzuki H
    Antiviral Res; 2013 Sep; 99(3):261-9. PubMed ID: 23791870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2015-2016.
    Gubareva LV; Besselaar TG; Daniels RS; Fry A; Gregory V; Huang W; Hurt AC; Jorquera PA; Lackenby A; Leang SK; Lo J; Pereyaslov D; Rebelo-de-Andrade H; Siqueira MM; Takashita E; Odagiri T; Wang D; Zhang W; Meijer A
    Antiviral Res; 2017 Oct; 146():12-20. PubMed ID: 28802866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of influenza virus resistance to neuraminidase inhibitors by an enzyme inhibition assay.
    Gubareva LV; Webster RG; Hayden FG
    Antiviral Res; 2002 Jan; 53(1):47-61. PubMed ID: 11684315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuraminidase inhibitors for the treatment and prevention of influenza.
    McKimm-Breschkin JL
    Expert Opin Pharmacother; 2002 Feb; 3(2):103-12. PubMed ID: 11829724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.